TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $122.70.

A number of brokerages have recently issued reports on TMDX. Robert W. Baird reduced their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Finally, TD Cowen cut their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th.

TransMedics Group Trading Up 3.9 %

Shares of NASDAQ:TMDX opened at $75.02 on Wednesday. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $177.37. The stock has a market cap of $2.52 billion, a PE ratio of 79.81 and a beta of 2.12. The business has a 50 day moving average of $65.92 and a 200-day moving average of $105.97. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of TransMedics Group by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock worth $226,700,000 after buying an additional 40,860 shares in the last quarter. FIL Ltd increased its holdings in shares of TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company’s stock worth $62,372,000 after buying an additional 218,961 shares in the last quarter. Braidwell LP acquired a new position in shares of TransMedics Group during the fourth quarter worth $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of TransMedics Group by 16.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company’s stock worth $56,307,000 after buying an additional 128,474 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of TransMedics Group by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 772,744 shares of the company’s stock worth $48,191,000 after buying an additional 8,954 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.